PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC
Industrials · Services-Commercial Physical & Biological Research · NC · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY10 | FY09 | FY08 | |
|---|---|---|---|
| Revenue | $1.47B | $1.42B | $1.55B |
| Operating income | $187.5M | $214.3M | $282.4M |
| Net income | $123.7M | $159.3M | $187.5M |
| Total assets | $1.99B | $2.03B | — |
| Total liabilities | $701.4M | $684.1M | — |
| Equity | $1.28B | $1.35B | $1.18B |
| EPS (diluted) | $1.04 | $1.34 | $1.56 |
| Shares out. | 119.0M | 118.3M | 120.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2010- Operating margin
- 12.7%
- Net margin
- 8.4%
- Return on equity
- 9.7%
- Return on assets
- 6.2%
- Return on capital (ROCE)
- 13.6%
- Liabilities / assets
- 35.2%
- Debt / equity
- 0.55×
- Book value / share
- $10.75
- Revenue growth (YoY)
- 3.8%
- Net income growth (YoY)
- −22.4%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2010- Altman Z″ (distress)
- 5.38safe
- Accruals / assets
- −6.2%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 6 good- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Amended charter or bylawsDec 5, 2011
- Shareholder voteNov 30, 2011
- Regulation FD disclosureNov 7, 2011
- Entered a material agreement · Other material eventOct 3, 2011
- Director / officer change · Regulation FD disclosureSep 22, 2011
- Results of operationsJul 26, 2011
- Regulation FD disclosureJul 18, 2011
- Shareholder voteMay 19, 2011
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4Mar 14, 2024
- 3/AFORM 3/ANov 8, 2021
- 3FORM 3Oct 18, 2021
- 4Aug 1, 2018
- 3Jul 25, 2018
- CT ORDERFeb 18, 2014
- CT ORDERDec 16, 2013
- 15-12GFORM 15-12GDec 15, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1Dec 6, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1Dec 6, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1Dec 6, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1Dec 6, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1Dec 6, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1Dec 6, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1Dec 6, 2011
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.